Get the Stockscreener App
3.30
3.77%
0.12
After Hours:
3.20
-0.10
-3.03%
Dare Bioscience Inc stock is traded at $3.30, with a volume of 29,102.
It is up +3.77% in the last 24 hours and down -9.59% over the past month.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
See More
Previous Close:
$3.18
Open:
$3.18
24h Volume:
29,102
Relative Volume:
0.71
Market Cap:
$28.02M
Revenue:
-
Net Income/Loss:
$-30.16M
P/E Ratio:
-7.1739
EPS:
-0.46
Net Cash Flow:
$-39.49M
1W Performance:
+3.77%
1M Performance:
-9.59%
6M Performance:
+656.88%
1Y Performance:
+867.74%
1-Day Range:
$3.18
$3.345
1-Week Range:
$3.18
$3.42
52-Week Range:
$0.27
$4.60
Dare Bioscience Inc Stock (DARE) Company Profile
Name
Dare Bioscience Inc
Sector
Industry
Phone
858-926-7655
Address
3655 NOBEL DRIVE, SAN DIEGO, CA
Compare DARE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
3.30 | 28.02M | 0 | -30.16M | -39.49M | -0.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Dare Bioscience Inc Stock (DARE) Latest News
Analyzing Vistagen Therapeutics (NASDAQ:VTGN) and Daré Bioscience (NASDAQ:DARE) - Defense World
Daré Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates - MSN
Dare Bioscience (DARE) Upgraded to Buy: Here's What You Should Know - MSN
Dare Bioscience files to sell 2.75M shares of common stocks by selling shareholders - MSN
Daré Bioscience, Inc. (NASDAQ:DARE) Q3 2024 Earnings Call Transcript - Insider Monkey
Dare Bioscience Inc (DARE) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance
Dare Bioscience Inc (DARE) Q3 2024 Earnings Call Highlights: Str - GuruFocus.com
Dare Bioscience Inc (DARE) Quarterly 10-Q Report - Quartzy
Form 10-Q Dare Bioscience, Inc. For: Sep 30 - StreetInsider.com
Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update - GlobeNewswire
Daré Bioscience Secures $35.7M in Funding, Cuts R&D Costs by 60% in Q3 Report | DARE Stock News - StockTitan
Daré Bioscience Announces Grant to Support Development of a - GlobeNewswire
Daré Bioscience secures $10.7 million grant from Gates Foundation - Investing.com India
Daré Bioscience secures $10.7 million grant from Gates Foundation By Investing.com - Investing.com UK
Daré Bioscience Lands $10.7M Gates Foundation Grant for Novel Contraceptive Development | DARE Stock News - StockTitan
Daré Bioscience (DARE) Scheduled to Post Earnings on Thursday - Defense World
Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024 - The Manila Times
Daré Bioscience to Host Third Quarter 2024 Financial - GlobeNewswire
Daré Bioscience to Report Q3 2024 Earnings, Host Conference Call November 14 | DARE Stock News - StockTitan
Daré Lands $25M for Women-Centric Pipeline - San Diego Business Journal
Dare BioscienceCatering To Women - RTTNews
Is Bavarian Nordic (BVNRY) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Will It Be A December To Remember For Daré Bioscience? - RTTNews
Daré Bioscience (NASDAQ:DARE) Publishes Corporate Presentation - Defense World
Daré Bioscience Enhances Investor Engagement with New Presentation - TipRanks
Daré Bioscience enters into $15M stock purchase agreement - MSN
Dare Bioscience shares retain Buy rating on funding reward By Investing.com - Investing.com Canada
FemTech start-ups share in $110m Sprint for Women's Health - substack.com
Dare Bioscience awarded $10M for HPV treatment development - Investing.com India
Dare Bioscience awarded $10M for HPV treatment development By Investing.com - Investing.com South Africa
Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health - The Bakersfield Californian
Daré Bioscience Enters Purchase Agreement with Lincoln Park Capital Fund - Defense World
Dare Bioscience secures $15 million funding agreement By Investing.com - Investing.com Australia
Dare Bioscience secures $15 million funding agreement - Investing.com
Daré Bioscience Announces Common Stock Purchase Agreement - GlobeNewswire
Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC - StockTitan
Brookline Capital Downgrades Daré Bioscience (DARE) - MSN
Bill Gates helped fund birth control microchip but didn't invent it | Fact check - USA TODAY
Dye & Durham Limited - Baystreet.ca
DADA’s 2023 Market Dance: Down -64.46% – Time to Invest? - The InvestChronicle
Barrow Hanley Mewhinney & Strauss LLC Raises Stake in Darling Ingredients Inc. (NYSE:DAR) - Defense World
Darling Ingredients Inc. (NYSE:DAR) Shares Sold by Meiji Yasuda Asset Management Co Ltd. - Defense World
MDA Space shares target raised on Telesat Lightspeed deals By Investing.com - Investing.com Australia
The Dare Announce 2024 Australian Headlining Shows - Music Feeds
The Dare Shares Inaugural Australian Tour Dates - The Music
ADMA Biologics stock soars to all-time high of $19.36 - Investing.com
The massive, untapped opportunity in women’s health - BioWorld Online
Daré Bioscience (NASDAQ:DARE) Share Price Crosses Below Two Hundred Day Moving Average of $4.51 - Defense World
Daré Bioscience (NASDAQ:DARE) Stock Price Passes Below Two Hundred Day Moving Average of $4.59 - Defense World
Its Stock Has Paid Off Big Time For Dare Bioscience Inc - SETE News
Dare Bioscience Inc Stock (DARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):